Company Profile

AUROBINDO PHARMA LTD.

NSE : AUROPHARMABSE : 524804ISIN CODE : INE406A01037Industry : Pharmaceuticals & DrugsHouse : Aurobindo
BSE1016.25-14.55 (-1.41 % )
PREV CLOSE (Rs.) 1030.80
OPEN PRICE (Rs.) 1038.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 167838
TODAY'S LOW / HIGH (Rs.)1005.00 1038.95
52 WK LOW / HIGH (Rs.)655 1063.75
NSE1017.30 -13.6 (-1.32 % )
PREV CLOSE(Rs.) 1030.90
OPEN PRICE (Rs.) 1034.90
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 1017.30 (2286 )
VOLUME 2777776
TODAY'S LOW / HIGH(Rs.) 1005.05 1039.00
52 WK LOW / HIGH (Rs.)654.6 1063.9

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.02
Dividend Yield(%) 0.29
TTM EPS (Rs.) 50.89
P/E Ratio 20.04
Book Value (Rs.) 246.88
Face Value (Rs.) 1
MCap (Rs. in Mn) 597540.19
Price/Earning (TTM) 17.26
Price/Sales (TTM) 3.98
Price/Book (MRQ) 4.13
PAT Margin (%) 14.07
ROCE (%) 16.05
Incorporation Year : 1986

Management Info :

K Ragunathan - Chairman N Govindarajan - Managing Director

Registered Office :

Address : Plot No. 2,Maitrivihar ,Ameerpet,
Hyderabad,
Telangana-500038

Phone : +91-040-66725000

Website : www.aurobindo.com

Registrar's Details : K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
31Mar03-31-2021$ Announcement under Regulation 30 (LODR)-Newspaper Publication Announcement under Regulati
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herewith enclose copies of the notice for the attention of equity shareholders of the Company in respect of transfer of equity shares of the Company to Investor Education and Protection Fund (IEPF) Account, published on Wednesday, 31st March 2021 in the following newspapers in accordance with the requirements of Section 124(6) of the Companies Act, 2013 read with Investor Education and Protection Fund (IEPF) Authority (Accounting, Audit, Transfer and Refund) Rules, 2016: Business Standard (English daily) Nava Talangana (Telugu daily).
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disc..
01Mar03-01-2021$ Information Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 Information Under Regulatio
The Board of Directors of Aurobindo Pharma Limited ('the Company') at its meeting held today i.e. February 27, 2021, has approved the following: 1) Transfer of all equity shares held in Lyfius Pharma Private Limited, a wholly owned subsidiary of the Company, to Aurobindo Antibiotics Private Limited, another wholly owned subsidiary of the Company. 2) Transfer of all equity shares held in Qule Pharma Private Limited, a wholly owned subsidiary of the Company, to Aurobindo Antibiotics Private Limited, another wholly owned subsidiary of the Company. 3) Transfer of business undertaking comprised in Unit-10, on a going concern basis, to APL Healthcare Limited, a wholly owned subsidiary of the Company.
The Board of Directors of Aurobindo Pharma Limited ('the Compan..
25Feb02-25-2021$Aurobindo Pharma informs about transcript of earnings call Aurobindo Pharma informs abo

With reference to its letter dated February 9, 2021 wherein the company had intimated the schedule of Investors/ Analysts call on February 11, 2021. Aurobindo Pharma has informed that it has enclosed the Transcript of the analyst / investor call on the Un-audited Financial Results of the Company for the third quarter and nine months period ended December 31, 2020 and the same is being uploaded on the website of the Company and is available in the following web link: https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/.

The above information is a part of company’s filings submitted to BSE.

With reference to its letter dated February 9, 2021 wherein the..
24Feb02-24-2021$Aurobindo Pharma inks pact to invest in two solar power companies Aurobindo Pharma inks pact t

Aurobindo Pharma has entered into binding agreements to invest Rs 5.38 crore each in NVNR (Ramannapet I) Power Plant and NVNR (Ramannapet II) Power Plant, aggregating to Rs 10.76 crore. The company has invested in the two firms to avail the benefit of captive consumption of solar power. After making the said investments, the company will be holding 26 percent of the share capital in each of the aforesaid solar power generating companies.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma has entered into binding agreements to invest..
24Feb02-24-2021$Aurobindo Pharma trades marginally higher on inking pact to invest in two solar power companies Aurobindo Pharma trades marg

Aurobindo Pharma is currently trading at Rs. 859.25, up by 3.25 points or 0.38% from its previous closing of Rs. 856.00 on the BSE.

The scrip opened at Rs. 869.00 and has touched a high and low of Rs. 869.00 and Rs. 856.15 respectively. So far 10398 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1023.10 on 25-Jan-2021 and a 52 week low of Rs. 281.15 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 925.00 and Rs. 837.50 respectively. The current market cap of the company is Rs. 50156.34 crore.

The promoters holding in the company stood at 51.94%, while Institutions and Non-Institutions held 37.60% and 10.47 /% respectively.

Aurobindo Pharma has entered into binding agreements to invest Rs 5.38 crore each in NVNR (Ramannapet I) Power Plant and NVNR (Ramannapet II) Power Plant, aggregating to Rs 10.76 crore. The company has invested in the two firms to avail the benefit of captive consumption of solar power. After making the said investments, the company will be holding 26 percent of the share capital in each of the aforesaid solar power generating companies.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma is currently trading at Rs. 859.25, up by 3.25..
Financials More
Rs. in Millions
QTR Dec 20 ANNUAL 20
Net Profit7405.1000000000118727.4
Gross Profit 10122.5 23777
Operating Profit 11387.229437.6
Net Sales 37108.6132664.8
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
NGL Fine-Chem (BSE)
 1679.60 (4.62%)
M.Cap ( in Cr)
1037.66
Ajanta Pharma (BSE)
 2010.70 (3.51%)
M.Cap ( in Cr)
17398.94
Solara Active Pharma (BSE)
 1748.00 (3.11%)
M.Cap ( in Cr)
6280.52
Themis Medicare (BSE)
 479.85 (8.78%)
M.Cap ( in Cr)
440.91
Abbott India (BSE)
 16220.00 (0.16%)
M.Cap ( in Cr)
34466.37
Shareholding Pattern More
MUTUAL FUNDS/UTI 8.84 %
PROMOTERS 51.94 %
FI/BANKS/INSURANCE 2.15 %
NON-INSTITUTION 10.45 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes